US20050159486A1 - Methods and compositions for the attenuation and/or prevention of stress/catabolic responses - Google Patents
Methods and compositions for the attenuation and/or prevention of stress/catabolic responses Download PDFInfo
- Publication number
- US20050159486A1 US20050159486A1 US11/076,290 US7629005A US2005159486A1 US 20050159486 A1 US20050159486 A1 US 20050159486A1 US 7629005 A US7629005 A US 7629005A US 2005159486 A1 US2005159486 A1 US 2005159486A1
- Authority
- US
- United States
- Prior art keywords
- cis
- trans
- conjugated linoleic
- linoleic acid
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 230000004044 response Effects 0.000 title description 9
- 230000001925 catabolic effect Effects 0.000 title description 7
- 230000002265 prevention Effects 0.000 title description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 38
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 claims abstract description 37
- 229940108924 conjugated linoleic acid Drugs 0.000 claims abstract description 37
- 230000006609 metabolic stress Effects 0.000 claims abstract description 26
- 238000001356 surgical procedure Methods 0.000 claims description 18
- ADHNUPOJJCKWRT-JLXBFWJWSA-N (2e,4e)-octadeca-2,4-dienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C(O)=O ADHNUPOJJCKWRT-JLXBFWJWSA-N 0.000 claims description 15
- IOCYQQQCJYMWDT-UHFFFAOYSA-N (3-ethyl-2-methoxyquinolin-6-yl)-(4-methoxycyclohexyl)methanone Chemical compound C=1C=C2N=C(OC)C(CC)=CC2=CC=1C(=O)C1CCC(OC)CC1 IOCYQQQCJYMWDT-UHFFFAOYSA-N 0.000 claims description 15
- 206010006895 Cachexia Diseases 0.000 claims description 10
- 208000017667 Chronic Disease Diseases 0.000 claims description 9
- 208000008589 Obesity Diseases 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 230000000747 cardiac effect Effects 0.000 claims description 5
- 239000002207 metabolite Substances 0.000 claims description 5
- 239000002243 precursor Substances 0.000 claims description 5
- 239000008122 artificial sweetener Substances 0.000 claims description 4
- 235000021311 artificial sweeteners Nutrition 0.000 claims description 4
- -1 cis-8 Chemical class 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 230000008901 benefit Effects 0.000 description 11
- 230000003938 response to stress Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010007733 Catabolic state Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical class CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000007675 cardiac surgery Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003023 adrenocorticotropic effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000009097 homeostatic mechanism Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001265 toxicological assessment Toxicity 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
Definitions
- approximately 500 mg to about 10,000 mg per day of conjugated linoleic acid are administered.
- the present invention provides a method of reducing the risk of morbidity and mortality of a patient who has had cardiac bypass surgery comprising the step of administering a therapeutically effective amount of a composition including conjugated linoleic acid to a patient that will undergo or has had cardiac surgery.
- An advantage of the present invention is that is provides a method and composition for the attenuation of metabolic stress and/or catabolic response.
- compositions of present invention may minimize the stress response.
- the compositions will also assist in the restoration of the normal homeostatic mechanisms underlying metabolic processes.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Methods and compositions for treating metabolic stress are provided. The method comprises the steps of administering a therapeutically effective amount of conjugated linoleic acid.
Description
- The present invention relates generally to compositions and methods for the treatment of disease states. More specifically, the present invention relates to compositions and methods for managing or preventing catabolic stress.
- Many diseases are known to be associated with metabolic stress condition. These acute or chronic illnesses can either initiate and/or maintain a metabolic stress condition. The metabolic stress condition has been demonstrated clinically through such events as adverse response to trauma, obesity, cancer, transfusions, acute and chronic diseases, various types of surgery, immunological disorders, and infections.
- Although such metabolic stress is known and has been demonstrated, there are few therapeutic options for treating such conditions. As a result, over a period of time, individuals remain in a persistent catabolic state, unable to overcome the physiological effects of these catabolic agents.
- An example of such a condition is that associated with chronic obesity. In this condition, despite adherence to a variety dietary and medical interventions, these individuals are unable to lose weight due, in part, to the underlying metabolic stress response. Such a response may be characterized by chronically elevated levels of cortisol, glucagon, adrenocorticotropic hormones, cytokines and other associated compounds.
- Metabolic stress can also be associated with cachexia. In this regard, due to illness, such as cancer or chronic immune disorders, metabolic stress can be induced that results in cachexia.
- Another example of a metabolic stress condition relates to the delayed stress response sometimes accompanying cardiac bypass surgery. While most patients exhibit favorable results for up to 60 days following such a procedure, evidence suggests the existence of a delayed stress response which may significantly influence morbidity and mortality following cardiac bypass surgery. This delayed response can occur for up to two years after the surgery.
- To address stress response accompanying acute and chronic illness as well as to treat stress response associated with invasive procedures and trauma, generally steroidal compounds have been administered. It is believed that although there is a moderate symptomatic suppression of the stress response through the use of steroids, this treatment can be accompanied by significant side effects and long-term consequences.
- Accordingly, there is a need for improved methods of treatment and compositions for treating and preventing metabolic stress.
- The present invention relates to methods and compositions for the attenuation, prevention, and/or management of the metabolic stress/catabolic response. In this regard, the present invention can be used to address metabolic stress conditions such as those associated with but not limited to, for example, various types of surgery, auto-immune disorders, and infections.
- To this end, the present invention provides a method for preventing or minimizing the onset of metabolic stress in an individual that may be susceptible to same, comprising the step of administering a therapeutically effective amount of a composition including conjugated linoleic acid.
- In an embodiment, approximately 500 mg to about 10,000 mg per day of conjugated linoleic acid are administered.
- In an embodiment, the individual recently had surgery.
- In an embodiment, the individual recently had an acute illness.
- In an embodiment, the individual has a chronic illness.
- In an embodiment, the conjugated linoleic acid is either a pure isomer of octadecadienoic acid, or a mixture of octadecadienoic acid isomers selected from the group consisting of: cis-8, cis-10; cis-8, trans-10; trans-8, cis-10; trans-8, trans-10; cis-9, cis-11; cis-9, trans-11; trans-9, cis-11; trans-9, trans-11; cis-10, cis 12; cis-9, trans-12; trans-9, cis-12; trans-10, trans-12; cis-11, cis-13; cis-11, trans-13; trans-11, cis-13; trans-11, trans-13 octadecadienoic acid; metabolites thereof, including but not limited to 18:3 cis-6, cis-9, trans 11; 18:3 cis-6, trans-10, cis-12; 18:3 cis-8, trans-12, cis-14; 20:3 cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, trans-12, cis-14; as well as precursors or derivatives thereof.
- In an embodiment, the composition includes a flavor.
- In an embodiment, the composition includes an artificial sweetener.
- In another embodiment of the present invention, a method of reducing the effects of metabolic stress in an individual suffering from metabolic stress is provided. The method comprising the step of administering a therapeutically effective amount of a composition including conjugated linoleic acid.
- In an embodiment, approximately 500 mg to about 10,000 mg per day of conjugated linoleic acid are administered.
- In an embodiment, the individual is preparing for, or recovering from invasive surgery.
- In an embodiment, the individual has a chronic illness.
- Still further, the present invention provides a method of treating chronic obesity. The method comprising the step of administering a therapeutically effective amount of a composition including conjugated linoleic acid to an individual suffering from chronic obesity.
- Additionally, the present invention provides a method of preventing or treating cachexia associated with metabolic stress, comprising the step of administering a therapeutically effective amount of a composition including conjugated linoleic acid to a patient who is expected to experience cachexia, or is having cachexia associated with metabolic stress.
- Additionally, the present invention provides a method of reducing the risk of morbidity and mortality of a patient who has had cardiac bypass surgery comprising the step of administering a therapeutically effective amount of a composition including conjugated linoleic acid to a patient that will undergo or has had cardiac surgery.
- In an embodiment, the composition is administered to the patient some time prior to or after the surgery but prior to two years after the surgery.
- An advantage of the present invention is that is provides a method and composition for the attenuation of metabolic stress and/or catabolic response.
- A further advantage of the present invention is that it provides a method for preventing or at least reducing the risk of metabolic stress.
- An additional advantage of the present invention is that it provides a method and composition for treating persistent catabolic state.
- Another advantage of the present invention is that it provides a method and composition for treating chronic obesity related to metabolic stress.
- Still, an advantage of the present invention is that it provides a method and composition for assisting patients who are unable to prevent weight gain or to lose weight.
- Furthermore, an advantage of the present invention is that it provides a method and composition for reducing morbidity and mortality following cardiac bypass surgery.
- Still further, an advantage of the present invention is that it provides a method and composition for aiding in the recovery of patients who have had invasive surgery.
- Additionally, an advantage of the present invention is that it provides a method of preventing or treating metabolic stress and/or cachexia associated with illness.
- Still further, an advantage of the present invention is that is provides a method and composition for enhancing the general health and well-being of patients suffering from metabolic disfunctions.
- These and other advantages and features present invention are described in and will be apparent from the detailed description of pressing preferred embodiment.
- The present invention provides methods and compositions for the attenuation and prevention of metabolic stress and/or catabolic response. The compositions of the present invention can be administered as a nutritional supplement, over-the-counter product, or pharmaceutical product, or as a component of pharmaceutical agents.
- Pursuant to the present invention the composition includes conjugated linoleic acid. Conjugated linoleic acid is utilized to influence those physiological processes associated with induction and maintenance of catabolic stress. Through its modulating effect on specific cytokines and pro-inflammatory prostaglandins, conjugated linoleic acid minimizes the expression of IL-1, IL-6, TNFα, and PGE2.
- Generally, pursuant to the present invention, it is envisioned that the composition of the present invention will be administered for a defined period before and/or after a period of stress initiation. The conjugated linoleic acid will serve to minimize the stimulation and/or propagation of the stress response. This will enhance the general health and well-being as well as improve recovering from conditions initiating metabolic stress. Such conditions include, but are not limited to, cardiac surgery, acute and chronic illnesses, asthma, and other metabolic dysfunctions.
- The compositions of present invention may minimize the stress response. The compositions will also assist in the restoration of the normal homeostatic mechanisms underlying metabolic processes.
- The ingredients that are used in the compositions of present invention are preferably all naturally occurring substances or derived therefrom; the active ingredients are all naturally occurring substances or derived therefrom. As compared to prior treatments and compositions, the present invention provides a less expensive alternative with no foreseeable side effects.
- Pursuant to the present invention, the method and composition comprises administering conjugated linoleic acid. If desired, the composition can include non-active ingredients and/or agents such as flavors, artificial sweeteners, excipients, etc. The product of the present invention is intended to provide a physiologically based means to aid in maintaining normal physiological homeostasis.
- Conjugated linoleic acid refers to a group of dienoic derivatives of linoleic acid that occur naturally in milk and meat of ruminating animals. It can be synthesized in the laboratory and is available commercially as a dietary supplement.
- Conjugated linoleic acid is believed to be absorbed efficiently into the body in a manner similar to that of other fatty acids, e.g., linoleic acid. The safety of conjugated linoleic acid has been demonstrated in detailed toxicological assessments and through extensive use in humans, both as a naturally occurring substance and as a dietary supplement. It is believed that conjugated linoleic acid is safe for human consumption.
- Pursuant to the present invention, the conjugated linoleic acid can be conjugated linoleic acid such as that set forth in U.S. Pat. No. 5,986,116 the disclosure of which is incorporated herein by reference.
- In an embodiment, the conjugated linoleic acid is either a pure isomer of octadecadienoic acid, or a mixture of octadecadienoic acid isomers selected from the group consisting of: cis-8, cis-10; cis-8, trans-10; trans-8, cis-10; trans-8, trans-10; cis-9, cis-11; cis-9, trans-11; trans-9, cis-11; trans-9, trans-11; cis-10, cis-12;
- cis-9, trans-12; trans-9, cis-12; trans-10, trans-12; cis-11, cis-13; cis-11, trans-13; trans-11, cis-13; trans-11, trans-13 octadecadienoic acid; metabolites thereof, including but not limited to 18:3 cis-6, cis-9, trans-11; 18:3 cis-6, trans-10, cis-12; 18:3 cis-8, trans-12, cis-14; 20:3 cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, trans-12, cis-14; as well as precursors or derivatives thereof.
- In an embodiment, the present invention comprises a method comprising providing to a patient approximately:
- 500 mg to about 10,000 mg of conjugated linoleic acid per day.
- In a most preferred embodiment of the method, the method provides approximately:
- 500 mg to about 6,000 mg of conjugated linoleic acid per day.
- Pursuant to the present invention, the composition can be taken as a dietary supplement or a pharmacological product.
- By way of example and not limitation, contemplative examples of the present invention are as follows:
- In order to treat stress-catabolic response sufficient product will be administered so that the patient receives 500 mg to 10,000 mg of conjugated linoleic acid per day. It is believed that this level of conjugated linoleic acid will at least reduce the effects of metabolic stress.
- In order to treat cachexia associated with chronic illness, sufficient product would be administered to provide 500 mg to about 10,000 mg of conjugated linoleic acid per day. It is believed that at such levels the cachexia should be at least reduced.
- It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its intended advantages. It is therefore intended that such changes and modifications be covered by the appended claims.
Claims (21)
1. A method for preventing the onset of metabolic stress in an individual comprising the step of administering a therapeutically effective amount of a composition including conjugated linoleic acid.
2. The method of claim 1 wherein approximately 500 mg to about 10,000 mg per day of conjugated linoleic acid are administered.
3. The method of claim 1 wherein the individual is preparing for surgery, or recently had surgery.
4. The method of claim 1 wherein the individual recently had an acute illness.
5. The method of claim 1 wherein the individual has a chronic illness.
6. The method of claim 1 wherein the conjugated linoleic acid is chosen from the group consisting of a pure isomer of octadecadienoic acid and a mixture of octadecadienoic acid isomers including: cis-8, cis-10; cis-8, trans-10; trans-8, cis-10; trans-8, trans-10; cis-9, cis-11; cis-9, trans-11; trans-9, cis-11; trans-9, trans-11; cis-10, cis-12; cis-9 trans-12; trans-9, cis-12; trans-10, trans-12; cis-11, cis-13; cis-11, trans-13; trans-11, cis-13; trans-11, trans-13 octadecadienoic acid; 18:3 cis-6, cis-9, trans-11; 18:3 cis-6, trans-10, cis-12; 18:3 cis-8, trans-12, cis-14; 20:3 cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, trans-12, cis-14; metabolites thereof; and precursors and derivatives thereof.
7. The method of claim 1 wherein the composition includes a flavor.
8. The method of claim 1 wherein the composition includes an artificial sweetener.
9. A method of reducing the treating of metabolic stress in an individual suffering from same comprising the step of administering a therapeutically effective amount of a composition including conjugated linoleic acid.
10. The method of claim 9 wherein approximately 500 mg to about 10,000 mg per day of conjugated linoleic acid are administered.
11. The method of claim 9 wherein the individual is preparing for or recovering from invasive surgery.
12. The method of claim 9 wherein the individual has a chronic illness.
13. The method of claim 9 wherein the conjugated linoleic acid is chosen from the group consisting of a pure isomer of octadecadienoic acid and a mixture of octadecadienoic acid isomers including: cis-8, cis-10; cis-8, trans-10; trans-8, cis-10; trans-8, trans-10; cis-9, cis-11; cis-9, trans-11; trans-9, cis-11; trans-9, trans-11; cis-10, cis-12; cis-9, trans-12; trans-9, cis-12; trans-10, trans-12; cis-11, cis-13; cis-11, trans-13; trans-11, cis-13; trans-11, trans-13 octadecadienoic acid; 18:3 cis-6, cis-9, trans-11; 18:3 cis-6, trans-10, cis-12; 18:3 cis-8, trans-12, cis-14; 20:3 cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, trans-12, cis-14; metabolites thereof; and precursors and derivatives thereof.
14. The method of claim 9 wherein the composition includes a flavor.
15. The method of claim 9 wherein the composition includes an artificial sweetener.
16. A method of treating chronic obesity comprising the step of administering a therapeutically effective amount of a composition including conjugated linoleic acid
17. The method of claim 16 wherein approximately 500 mg to about 10,000 mg per day of conjugated linoleic acid are administered.
18. The method of claim 16 wherein wherein the conjugated linoleic acid is chosen from the group consisting of a pure isomer of octadecadienoic acid and a mixture of octadecadienoic acid isomers including: cis-8, cis-10; cis-8, trans-10; trans-8, cis-10; trans-8, trans-10; cis-9, cis-11; cis-9, trans-11; trans-9, cis-11; trans-9, trans-11; cis-10, cis-12; cis-9, trans-12; trans-9, cis-12; trans-10, trans-12; cis-11, cis-13; cis-11, trans-13; trans-11, cis-13; trans-11, trans-13 octadecadienoic acid; 18:3 cis-6, cis-9, trans-11; 18:3 cis-6, trans-10, cis-12; 18:3 cis-8, trans-12, cis-14; 20:3 cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, trans-12, cis-14; metabolites thereof; and precursors and derivatives thereof.
19. A method of preventing or treating cachexia comprising the step of administering a therapeutically effective amount of a composition including conjugated linoleic acid to a patient having or at risk to have cachexia.
20. A method of reducing the risk of mortality for a patient that will have or has had cardiac bypass surgery comprising the step of administering a therapeutically effective amount of a composition including conjugated linoleic acid to a patient that has had cardic bypass surgery.
21. The method of claim 20 wherein the composition is administered at any time prior to two years after the bypass surgery.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/076,290 US20050159486A1 (en) | 2000-08-02 | 2005-03-08 | Methods and compositions for the attenuation and/or prevention of stress/catabolic responses |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/333,299 US6927239B1 (en) | 2000-08-02 | 2000-08-02 | Methods and compositions for the attenuation and/or prevention of stress/catabolic responses |
| PCT/US2000/021047 WO2002009692A1 (en) | 2000-08-02 | 2000-08-02 | Methods and compositions for the attenuation and/or prevention of stress/catabolic responses |
| US11/076,290 US20050159486A1 (en) | 2000-08-02 | 2005-03-08 | Methods and compositions for the attenuation and/or prevention of stress/catabolic responses |
Related Parent Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/333,299 Continuation US6927239B1 (en) | 2000-08-02 | 2000-08-02 | Methods and compositions for the attenuation and/or prevention of stress/catabolic responses |
| PCT/US2000/021047 Continuation WO2002009692A1 (en) | 2000-08-02 | 2000-08-02 | Methods and compositions for the attenuation and/or prevention of stress/catabolic responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20050159486A1 true US20050159486A1 (en) | 2005-07-21 |
Family
ID=34748677
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/333,299 Expired - Fee Related US6927239B1 (en) | 2000-08-02 | 2000-08-02 | Methods and compositions for the attenuation and/or prevention of stress/catabolic responses |
| US11/076,290 Abandoned US20050159486A1 (en) | 2000-08-02 | 2005-03-08 | Methods and compositions for the attenuation and/or prevention of stress/catabolic responses |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/333,299 Expired - Fee Related US6927239B1 (en) | 2000-08-02 | 2000-08-02 | Methods and compositions for the attenuation and/or prevention of stress/catabolic responses |
Country Status (1)
| Country | Link |
|---|---|
| US (2) | US6927239B1 (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4851426A (en) * | 1982-12-09 | 1989-07-25 | Teva Pharmaceutical Industries, Ltd. | Ethoxycarbonyloxy ethyl esters of non-steroidal anti-inflammatory carboxylic acids and pharmaceutical compositions thereof |
| US4981844A (en) * | 1988-10-04 | 1991-01-01 | University Of Cincinnati | Method to improve immune response and resistance to infection following surgery by diet composition |
| US5430006A (en) * | 1992-09-28 | 1995-07-04 | Bayer Aktiengesellschaft | Herbicidal substituted thienylsulphonylureas |
| US5603959A (en) * | 1994-03-01 | 1997-02-18 | Scotia Holdings Plc | Fatty acid derivatives |
| US5886037A (en) * | 1996-11-20 | 1999-03-23 | N.V. Nutricia | Nutritional composition for the treatment of hypertriglyceridaemia and hyperchylomicronaemia |
| US5986116A (en) * | 1996-10-30 | 1999-11-16 | Rinoru Oil Mills Co., Ltd. | Method for producing conjugated linoleic acid |
| US6034132A (en) * | 1998-01-05 | 2000-03-07 | Natural Nutrition Ltd. As | Method of reducing bodyweight and treating obesity |
| US6060514A (en) * | 1998-05-04 | 2000-05-09 | Conlin Co., Inc. | Isomer enriched conjugated linoleic acid compositions |
| US6838451B1 (en) * | 2000-08-02 | 2005-01-04 | Pharmanutrients | Methods and compositions for the prevention and treatment of inflammation, osteoarthritis, and other degenerative joint diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5430066A (en) * | 1992-04-29 | 1995-07-04 | Wisconsin Alumni Research Foundation | Methods for preventing weight loss, reduction in weight gain, and anorexia due to immune stimulation |
| MY118354A (en) * | 1995-05-01 | 2004-10-30 | Scarista Ltd | 1,3-propane diol derivatives as bioactive compounds |
| GB9622636D0 (en) * | 1996-10-30 | 1997-01-08 | Scotia Holdings Plc | Presentation of bioactives |
| ES2252874T3 (en) | 1997-12-12 | 2006-05-16 | Purdue Research Foundation | USE OF CONJUGATED LINOLEIC ACID FOR TREATMENT OF MELLITUS TYPE II DIABETES. |
-
2000
- 2000-08-02 US US10/333,299 patent/US6927239B1/en not_active Expired - Fee Related
-
2005
- 2005-03-08 US US11/076,290 patent/US20050159486A1/en not_active Abandoned
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4851426A (en) * | 1982-12-09 | 1989-07-25 | Teva Pharmaceutical Industries, Ltd. | Ethoxycarbonyloxy ethyl esters of non-steroidal anti-inflammatory carboxylic acids and pharmaceutical compositions thereof |
| US4981844A (en) * | 1988-10-04 | 1991-01-01 | University Of Cincinnati | Method to improve immune response and resistance to infection following surgery by diet composition |
| US5430006A (en) * | 1992-09-28 | 1995-07-04 | Bayer Aktiengesellschaft | Herbicidal substituted thienylsulphonylureas |
| US5603959A (en) * | 1994-03-01 | 1997-02-18 | Scotia Holdings Plc | Fatty acid derivatives |
| US5986116A (en) * | 1996-10-30 | 1999-11-16 | Rinoru Oil Mills Co., Ltd. | Method for producing conjugated linoleic acid |
| US5886037A (en) * | 1996-11-20 | 1999-03-23 | N.V. Nutricia | Nutritional composition for the treatment of hypertriglyceridaemia and hyperchylomicronaemia |
| US6034132A (en) * | 1998-01-05 | 2000-03-07 | Natural Nutrition Ltd. As | Method of reducing bodyweight and treating obesity |
| US6060514A (en) * | 1998-05-04 | 2000-05-09 | Conlin Co., Inc. | Isomer enriched conjugated linoleic acid compositions |
| US6838451B1 (en) * | 2000-08-02 | 2005-01-04 | Pharmanutrients | Methods and compositions for the prevention and treatment of inflammation, osteoarthritis, and other degenerative joint diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| US6927239B1 (en) | 2005-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3046350C (en) | Glyceryl 3-hydroxybutyrates for migraine symptom management | |
| TW323230B (en) | ||
| JP2925326B2 (en) | Methods for promoting human nitrogen retention | |
| JPH0640904A (en) | Medicinal composition | |
| JP2007532663A (en) | Use of treprostinil to treat neuropathic diabetic foot ulcers | |
| JPH0692847A (en) | Therapeutic agent for osteoporosis | |
| JPH05178744A (en) | Method for medical treatment using fatty acid | |
| TWI331920B (en) | Unit dosage form for relieving or treating constipation in human patients | |
| JPS6377817A (en) | Therapeutical composition, manufacture and therapy thereby | |
| WO2002092067A1 (en) | Compositions for transmucosal administration containing coenzyme q as the active ingredient | |
| JPH06172169A (en) | Therapy by using fatty acid | |
| US6927239B1 (en) | Methods and compositions for the attenuation and/or prevention of stress/catabolic responses | |
| WO2002009692A1 (en) | Methods and compositions for the attenuation and/or prevention of stress/catabolic responses | |
| US6838451B1 (en) | Methods and compositions for the prevention and treatment of inflammation, osteoarthritis, and other degenerative joint diseases | |
| EP1498119A1 (en) | Use of conjugated linoleic acid for treating colds | |
| US4686225A (en) | Vinpocetine for pulmonary hemorrhage and edema | |
| US5173511A (en) | Method for treatment of allergies using glycerol ethers | |
| US7208522B1 (en) | Methods and compositions for the prevention and treatment of Syndrome X | |
| JP2836206B2 (en) | Oil composition for inflammatory bowel disease | |
| WO2002009725A1 (en) | Methods and compositions for the prevention and treatment of inflamation, osteoarthritis, and other degenerative joint diseases | |
| JPH0369889B2 (en) | ||
| JPS63230631A (en) | Use of essential fatty acid and prevention or treatment for digestive tumor | |
| RU2294204C1 (en) | Method for treatment of stomach and duodenum ulcerous disease | |
| BE829197A (en) | ANTI-INFLAMMATORY COMPOSITIONS, THEIR PREPARATION AND THEIR USE | |
| Shah et al. | Prostaglandin synthetase inhibitors and their effect on urinary calcium excretion and other parameters in idiopathic hypercalciuria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: PHARMANUTRIENTS, ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MENARD, MICHAEL;ROCKWAY, SUSIE;REEL/FRAME:016014/0170 Effective date: 20030623 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |